IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-α and DTIC

Clinical and Experimental Metastasis

Volumn 20, Issue 7, 2003, Pages 647-655

  Konjević, Gordana ^a,b   Jović, Viktor ^a   Jurišić, Vladimir ^c   Radulović, Siniša ^a   Jelić, Svetislav ^a   Spužić, Ivan ^a,b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Activation antigens; CD4+ T cells; DTIC and IFN ; IL 2; Metastatic melanoma; Nk cell activity; TNF

Indexed keywords

ALPHA2A INTERFERON; ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; DACARBAZINE; HLA DR ANTIGEN; INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPOTENTIATION; LYMPHOCYTE COUNT; MALE; MELANOMA; METASTASIS; NATURAL KILLER CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 0344873636     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027387930868     Document Type: Article

References (60)

1. Biron CA, Cousens LP, Ruzek MC et al. Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity. Adv Exp Med Biol 1998; 452: 143-9.
2. Hernberg M, Muhonen T, Pyrhönen S. Can the CD4+/CD8+ ratio predict the outcome of patients interferon-a therapy for renal cell carcinoma? Ann Oncol 1997; 8: 71-7.
3. Marrack P, Kappler, Mitchell T. Type I Interferons keep activated T cells alive. J Exp Med 1999; 189: 521-30.
4. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action. J Interferon Cytokine Res 1999; 19: 817-28.
5. Brittenden J, Heys SD, Ross J, Eremin O. Natural killer cells and cancer. Cancer 1996; 77: 1226-43.
6. Whiteside TI, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immnunol 1995; 7: 704-10.
7. Deniz G, Akdis M, Aktas E et al. Human NK1 and NK2 subsets determined by purification of IFN-gamma-secreting and IFN-gamma-non-secreting NK cells. Eur J Immunol 2002; 32: 879-84.
8. Yokoyama WM. Natural killer cells. Right-side-up and up-side-down NK-cell receptors. Curr Biol 1995; 5: 982-5.
9. Kono K, Salazar-Onfray F, Petersson M et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308-13.
10. Konjevic G, Jurisic V, Banicevic B, Spuzic I. The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol 1999; 104: 144-51.
11. Kirkwood JM, Richards T, Zarour HM et al. Immunomodulatory effects of high-dose and low-dose interferon alpha 2b in patients with high risk resected melanoma: the E2690 laboratory corollary of inter group adjuvant trial E1690. Cancer 2002; 95: 1101-12.
12. Borrego F, Kabat J, Kim DK et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol, 2002; 38: 637-660.
13. Palmieri G, Morrone S, Lollini PL et al. TNF impairs in vivo and in vitro natural killer (NK) susceptibility of B16 melanoma cells. Scan J Immunol 1992; 35: 279-89.
14. Ross ME, Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997; 89: 910-8.
15. Falkson CI. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 1995; 12: 35-40.
16. Roon IG, Inbar MJ, Gutman M et al. Recombinant interferon-2α in combination with dacarbazine in the treatment of metastaic malignant melanoma: Analysis of long-term responding patients. Cancer Immunol Immunother 1993; 37: 61-6.
17. Hoffman MA, Wadler S. Mechanisms by which interferon potentiates chemotherapy. Cancer Invest 1993; 11: 310-13.
18. Hernberg M, Muhonen T, Turunen JP et al. The CD4+/CD8+ ratio as a prognostic factor in patients treated with chemo-immunotherapy with metastatic melanoma. J Clin Oncol 1996; 14: 1690-6.
19. Conti L, Arista MC, Callopoli A et al. Flow cytometry evaluation of lymphocytes subsets in non-treated neoplastic patients. J Clin Exp Cancer Res 1995; 5: 257-64.
20. Konjevic G, Jurisic V, Spuzic I. Correction to the original lactate dehydrogenase (LDH) release assay for evaluation of NK cell cytotoxicity. J Immunol Meth, 1997; 200: 199-201.
21. Jurisic V, Spuzic I, Konjevic G. A comparison of NK cell activity with effects of TNF-alpha against K-562 cells, determined by LDH release assay. Cancer Lett 1999; 138: 67-72.
22. Johnston SR, Constenla DO, Moore J et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-6.
23. Steinhauer EH, Doyle AT, Reed J, Kadish AS, Defective natural cytotoxicity in patients with cancer: Normal number of effector cells but decreased recycling capacity in patients with advanced disease. J Immunol 1982; 129: 2255-9.
24. Zea AH, Curti BD, Longo DL et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995; 1: 1327-35.
25. Kishi A, Ohmori M, Tomita S et al. Phenotypic and functional analyses of natural killer cells: Impaired NK activity partly due to the CD56+ cell dysfunction in cancer patients. Int J Immunother 1999; 15: 1-12.
26. Sibbit WL, Bankhurst AD, Jumonville AJ et al. Defects in natural killer activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Res 1984; 44: 852-6.
27. Konjevic G, Jurisic V, Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 2001; 66: 255-263
28. Krasagakis K, Tholke D, Farthmann B et al. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 1998; 77: 1492-4.
29. Hafner M, Orosz P, Kruger A, Mannel DN. TNF promotes metastasis by impairing natural killer cell activity. Int J Cancer 1996; 66: 388-92.
30. Barlozzari, T, Leonhardt J, Wiltrout RH et al. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 1985; 134: 2783-9.
31. Konjevic G, Spuzic I. Jurisic V. In-vitro effects of cytokines and cytokines receptors on the activity of NK cells. J BUON 1996; 1: 47-52.
32. Smyth MJ, Thia KY, Cretney E et al. Perform is a major contributor to NK cell control of tumor metastasis. J Immunol 1999; 162: 6658-62.
33. Campbell JJ, Qin S, Unutmaz D et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001; 166: 6477-82.
34. Mersey P, Hasic E, Macdonald M et al. Effects of recombinant leukocyte interferon (rhIFN alpha A) on tumor growth and immune response in patients with metastatic melanoma. Br J Cancer 1985; 51: 815-26.
35. Eisenthal A, Skornick Y, Ron I et al. Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy. Cancer Immunol Immunother 1993; 37: 367-72.
36. Verhagen A, Mackay IR, Rowley M, Tymms M. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul 1990; 9: 325-33.
37. Chakir H, Camilucci AA, Filion LG, Webb JR. Differentiation of murine NK cells into distinct subsets based on variable expression of the IL-12R beta 2 subunit. J Immunol 2000; 165: 4985-93.
38. Konjevic G, Schlesinger B, Cheng L et al. Analysis of perform expression in human peripheral blood lymphocytes, CD56+ natural killer cell subsets and its induction by interleukin-2. Immunol Invest 1995; 24: 499-507.
39. Spaggiari GM, Contini P, Dondero A et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 2002; 100: 4098-107.
40. Golub SG, D'Amore PD, Rainey M. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cutotoxicity. J Nat Cancer Inst 1982; 68: 711-7.
41. Mogensen KE, Lewerenz M, Reboul J et al. The type I interferon receptor: Structure, function, and evolution of a family business. J Interferon Cytokine Res 1999; 19: 1069-98.
42. Bajetta, E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol, 1994; 12: 806-11.
43. Atkins MB Immunotherapy and experimental approaches for metastatic melanoma. Melanoma 1998; 12: 877-902.
44. Aulitzky, WE, Aulitzky W, Gastl G et al. Acute effects of single dose of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J Interferon Res 1989; 9: 425-33.
45. Testi R, D'ambrosio D, De Maria R, Santoni A. The CD69 receptor: Multipurpose cell surface trigger for hematopoietic cells. Immunol Today 1994; 15: 479-83.
46. Yacyshyn-Bowen, MB, Poppema S, Berg A et al. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlation with survival following active specific immunotherapy. Int J Cancer 1995; 61: 470-4.
47. Simms PE, Ellis TM. Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly-and oligoclonal lymphocyte activation. Clin Diag Lab Immunol 1996; 3: 301-4.
48. Borrego F, Robertson MJ, Ritz J et al. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. J Immunol 1999; 97: 159-65.
49. Pardoll DM, Topalian SL. The role of CD4 + T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-94.
50. Hakansson A, Gustaffson B, Krysander L. et al. On down-regulation of the immune response to metastatic melanoma. Cancer Immunol Immunother 1999; 48: 253-62.
51. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu Rev Immunol 1997; 15: 749-95.
52. Surman DR, Mark ED, Overwijk WW, Restifol NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000; 164: 562-5.
53. Dobrzanski MJ, Reome JB, Dutton RW et al. Type 1 and type 2 CD8+ effectors T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. Immunology 1999; 98: 535-40.
54. Bernengo MG, Lisa F, Meregalli M et al. Changes in T and B lymphocyte subpoulations before, during and after chemotherapy for malignant melanoma. Int J Tissue React 1984; 6: 505-11.
55. Pantaleo G, Koenig S, Baseler M et al. Defective clonogenic potential of CD8+ T-lymphocytes in patients with AIDS. Expansion in vivo of a non clonogenic CD3+CD8+DR+CD25-T cell population. J Immunol 1990; 144: 1696-704.
56. Funaro A, De Monte LB, Dianzani U et al. Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur J Immunol 1993; 23: 2407-11.
57. Mills CD, Kincaid K, Alt JM et al. M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J Immunol 2000; 164: 6166-73.
58. Degiannis D, Koniavitou K. In vitro expression of activation markers and lymphocyte proliferation in response to interleukin 12: Effect of immunosuppressive agents. Transpl Proc 1996; 28: 3062-4.
59. Reveneau S, Arnould L, Jolimoy G et al. Changes in sIL-6R and s TNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment. Cytokine 1998; 79: 540-3.
60. Zoll B, Lefterova P, Ebert O et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine 2000; 12: 1385-90.